Private Advisor Group LLC Purchases 60 Shares of Stryker Co. (NYSE:SYK)

Private Advisor Group LLC boosted its position in Stryker Co. (NYSE:SYK) by 0.4% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 16,027 shares of the medical technology company’s stock after acquiring an additional 60 shares during the quarter. Private Advisor Group LLC’s holdings in Stryker were worth $5,771,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in SYK. Assenagon Asset Management S.A. increased its position in Stryker by 15.6% in the 3rd quarter. Assenagon Asset Management S.A. now owns 10,304 shares of the medical technology company’s stock valued at $3,722,000 after buying an additional 1,392 shares in the last quarter. Global Trust Asset Management LLC bought a new stake in Stryker in the 3rd quarter valued at about $69,000. DT Investment Partners LLC increased its position in Stryker by 114.3% in the 3rd quarter. DT Investment Partners LLC now owns 135 shares of the medical technology company’s stock valued at $49,000 after buying an additional 72 shares in the last quarter. Trueblood Wealth Management LLC increased its position in Stryker by 7.6% in the 3rd quarter. Trueblood Wealth Management LLC now owns 2,841 shares of the medical technology company’s stock valued at $1,026,000 after buying an additional 200 shares in the last quarter. Finally, Lyell Wealth Management LP increased its position in Stryker by 0.7% in the 3rd quarter. Lyell Wealth Management LP now owns 33,849 shares of the medical technology company’s stock valued at $12,228,000 after buying an additional 236 shares in the last quarter. 77.09% of the stock is owned by institutional investors.

Insider Buying and Selling at Stryker

In other news, Director Ronda E. Stryker sold 201,392 shares of the firm’s stock in a transaction on Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the completion of the transaction, the director now directly owns 3,642,075 shares of the company’s stock, valued at $1,428,567,498. This trade represents a 5.24 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Allan C. Golston sold 2,458 shares of the firm’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the transaction, the director now directly owns 14,895 shares of the company’s stock, valued at $5,705,827.65. The trade was a 14.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is owned by corporate insiders.

Stryker Price Performance

Shares of NYSE SYK opened at $382.59 on Friday. The stock has a fifty day simple moving average of $378.07 and a two-hundred day simple moving average of $368.99. Stryker Co. has a 1-year low of $314.93 and a 1-year high of $406.19. The firm has a market cap of $145.99 billion, a price-to-earnings ratio of 49.30, a price-to-earnings-growth ratio of 2.93 and a beta of 0.96. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter last year, the business earned $3.46 earnings per share. Analysts anticipate that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be issued a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a yield of 0.88%. The ex-dividend date is Monday, March 31st. Stryker’s dividend payout ratio (DPR) is 43.30%.

Analyst Ratings Changes

A number of brokerages have commented on SYK. Royal Bank of Canada boosted their price objective on Stryker from $425.00 to $435.00 and gave the stock an “outperform” rating in a report on Wednesday, January 29th. UBS Group boosted their price objective on Stryker from $366.00 to $370.00 and gave the stock a “neutral” rating in a report on Wednesday, October 30th. Morgan Stanley raised Stryker from an “equal weight” rating to an “overweight” rating and boosted their price objective for the stock from $370.00 to $445.00 in a report on Monday, December 2nd. Stifel Nicolaus boosted their price objective on Stryker from $400.00 to $440.00 and gave the stock a “buy” rating in a report on Wednesday, January 29th. Finally, Truist Financial boosted their price objective on Stryker from $409.00 to $413.00 and gave the stock a “hold” rating in a report on Thursday, January 30th. Five equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $422.15.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.